Frequency of CHEK2 mutations in a population based, case–control study of breast cancer in young women

Breast Cancer Research

Elaine A Ostrander¹  Janet R Daling²  David R Doody³  Kathleen E Malone²  Danielle M Friedrichsen¹ 

[1] Divisions of Clinical Research and Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA;School of Public, Health and Community Medicine, Department of Epidemiology, University of Washington, Seattle, Washington, USA;Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

关键词: population based;    CHEK2;    case–control study;    breast cancer;   

Others  :  1118718
DOI  :  10.1186/bcr933

 received in 2004-05-10, accepted in 2004-08-11,  发布年份 2004

【 摘 要 】

Introduction

The cell-cycle checkpoint kinase (CHEK)2 protein truncating mutation 1100delC has been associated with increased risk for breast or prostate cancer. Multiple studies have found an elevated frequency of the 1100delC variant in specific stratifications of breast cancer patients with a family history of the disease, including BRCA1/BRCA2 negative families and families with a history of bilateral disease or male breast cancer. However, the 1100delC mutation has only been investigated in a few population-based studies and none from North America.

Methods

We report here on the frequency of three CHEK2 variants that alter protein function – 1100delC, R145W, and I175T – in 506 cases and 459 controls from a population based, case–control study of breast cancer conducted in young women from western Washington.

Results

There was a suggestive enrichment in the 1100delC variant in the cases (1.2%) as compared with the controls (0.4%), but this was based on small numbers of carriers and the differences were not statistically significant. The 1100delC variant was more frequent in cases with a first-degree family history of breast cancer (4.3%; P = 0.02) and slightly enriched in cases with a family history of ovarian cancer (4.4%; P = 0.09).

Conclusion

The CHEK2 variants are rare in the western Washington population and, based on accumulated evidence across studies, are unlikely to be major breast cancer susceptibility genes. Thus, screening for the 1100delC variant may have limited usefulness in breast cancer prevention programs in the USA.

【 授权许可】

   
Friedrichsen et al., licensee BioMed Central Ltd.

【 参考文献 】

• [1]Shieh SY, Ahn J, Tamai K, Taya Y, Prives C: The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000, 14:289-300.
• [2]Bartek J, Falck J, Lukas J: CHK2 kinase: a busy messenger. Nat Rev Mol Cell Biol 2001, 2:877-886.
• [3]Seppala EH, Ikonen T, Mononen N, Autio V, Rokman A, Matikainen MP, Tammela TL, Schleutker J: CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 2003, 89:1966-1970.
• [4]Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ, et al.: Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003, 72:270-280.
• [5]Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, et al.: Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002, 31:55-59.
• [6]Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, et al.: A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002, 71:432-438.
• [7]Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG, Hoogerbrugge N, Ligtenberg MJ, van Asperen CJ, Vasen HF, Meijers C, et al.: The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res 2003, 63:8153-8157.
• [8]Offit K, Pierce H, Kirchhoff T, Kolachana P, Rapaport B, Gregersen P, Johnson S, Yossepowitch O, Huang H, Satagopan J, et al.: Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med Genet 2003, 4:1. BioMed Central Full Text
• [9]Allinen M, Huusko P, Mantyniemi S, Launonen V, Winqvist R: Mutation analysis of the CHK2 gene in families with hereditary breast cancer. Br J Cancer 2001, 85:209-212.
• [10]Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG, Eccles D, Meijers C, Lohman F, Klijn J, et al.: Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet 2003, 72:1023-1028.
• [11]Osorio A, Rodriguez-Lopez R, Diez O, de la Hoya M, Ignacio Martinez J, Vega A, Esteban-Cardenosa E, Alonso C, Caldes T, Benitez J: The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population. Int J Cancer 2004, 108:54-56.
• [12]Rajkumar T, Soumittra N, Nancy NK, Swaminathan R, Sridevi V, Shanta V: BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India. Asian Pac J Cancer Prev 2003, 4:203-208.
• [13]Brinton LA, Daling JR, Liff JM, Schoenberg JB, Malone KE, Stanford JL, Coates RJ, Gammon MD, Hanson L, Hoover RN: Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 1995, 87:827-835.
• [14]Daling JR, Malone KE, Voigt LF, White E, Weiss NS: Risk of breast cancer among young women: relationship to induced abortion. J Natl Cancer Inst 1994, 86:1584-1592.
• [15]Waksberg J: Sample methods for random digit dialing. J Am Stat Soc 1978, 73:40-46.
• [16]Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomaki K, Nevanlinna H: p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 2001, 61:5718-5722.
• [17]Breslow NE, Day NE: Statistical Methods in Cancer Research. The Analysis of Case–control Studies. Lyon: IARC Scientific Publications; 1980.
• [18]Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV, Ostrander EA: BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 1998, 279:922-929.
• [19]Malone KE, Daling JR, Neal C, Suter NM, O'Brien C, Cushing-Haugen K, Jonasdottir TJ, Thompson JD, Ostrander EA: Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 2000, 88:1393-1402.
• [20]Wu X, Webster SR, Chen J: Characterization of tumor-associated Chk2 mutations. J Biol Chem 2001, 276:2971-2974.
• [21]Li J, Williams BL, Haire LF, Goldberg M, Wilker E, Durocher D, Yaffe MB, Jackson SP, Smerdon SJ: Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol Cell 2002, 9:1045-1054.
• [22]Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J: The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001, 410:842-847.
• [23]Broeks A, de Witte L, Nooijen A, Huseinovic A, Klijn JG, van Leeuwen FE, Russell NS, van't Veer LJ: Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat 2004, 83:91-93.
• [24]Syrjakoski K, Kuukasjarvi T, Auvinen A, Kallioniemi OP: CHEK2 1100delC is not a risk factor for male breast cancer population. Int J Cancer 2004, 108:475-476.
• [25]Neuhausen S, Dunning A, Steele L, Yakumo K, Hoffman M, Szabo C, Tee L, Baines C, Pharoah P, Goldgar D, Easton D: Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer 2004, 108:477-478.
• [26]Ohayon T, Gal I, Baruch RG, Szabo C, Friedman E: CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer 2004, 108:479-480.